Trials / Completed
CompletedNCT00611403
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion administered twice daily following LASIK surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) | Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery |
| DRUG | Artificial Tears REFRESH ENDURA® | REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-12-01
- Completion
- 2009-06-01
- First posted
- 2008-02-08
- Last updated
- 2011-12-20
- Results posted
- 2011-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00611403. Inclusion in this directory is not an endorsement.